Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company operates 2 divisions: Innovative Medicine (64% of 2025 revenues) and MedTech (36% of 2025 revenues). Major products produced by the Innovative Medicine division are CARVYKTI (ciltacabtagene autoleucel) for multiple myeloma (2.0% of revenues); DARZALEX (daratumumab and hyaluronidase-fihj), also for multiple myeloma (15.2% of revenues); ERLEADA (apalutamide), for prostate cancer (3.8% of revenues); REMICADE (infliximab), for inflammatory diseases (1.9% of revenues); SIMPONI/SIMPONI ARIA (golimumab), for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis (pJIA) (2.8% of revenues); STELARA (ustekinumab), for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis (6.5% of revenues); TREMFYA (guselkumab), for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis (5.5% of revenues); INVEGA SUSTENNA/XEPLION (paliperidone palmitate), for schizophrenia (4.1% of revenues); SPRAVATO (Esketamine), a nasal spray for depression (1.8% of revenues); OPSUMIT (macitentan)/OPSYNVI (macitentan/tadalafil) for pulmonary arterial hypertension (2.5% of revenues); and UPTRAVI (selexipag) for pulmonary arterial hypertension (2.0% of revenues). The MedTech division produces products used for cardiovascular (9.5% of revenues), orthopaedics (DePuy Synthes) (9.8% of revenues), surgery (Ethicon) (10.8% of revenues), and vision treatments (Johnson & Johnson Vision) (5.8% of revenues).
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| JNJ | JOHNSON & JOHNSON | 2026-06-01 15:22:49 | 223.51 | -1.72 | -0.76 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JNJ | 0000200406 | JOHNSON & JOHNSON | US4781601046 | 549300GQXUV37X4D2C47 | 221024240 | NYSE | 2834 | Pharmaceutical Preparations | 0103 | NJ | ONE JOHNSON & JOHNSON PLZ | NEW BRUNSWICK | NJ | 08933 | UNITED STATES | US | 732-524-2455 | ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ, 08933 | ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ, 08933 | JOHNSON & JOHNSON ET AL | Pharmaceutical | 1886 | Joaquin Duato | 138,200 | https://www.jnj.com/ | 367,000,000,000 | 3,119,843,000 | 2,407,216,971 | Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company operates 2 divisions: Innovative Medicine (64% of 2025 revenues) and MedTech (36% of 2025 revenues). Major products produced by the Innovative Medicine division are CARVYKTI (ciltacabtagene autoleucel) for multiple myeloma (2.0% of revenues); DARZALEX (daratumumab and hyaluronidase-fihj), also for multiple myeloma (15.2% of revenues); ERLEADA (apalutamide), for prostate cancer (3.8% of revenues); REMICADE (infliximab), for inflammatory diseases (1.9% of revenues); SIMPONI/SIMPONI ARIA (golimumab), for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis (pJIA) (2.8% of revenues); STELARA (ustekinumab), for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis (6.5% of revenues); TREMFYA (guselkumab), for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis (5.5% of revenues); INVEGA SUSTENNA/XEPLION (paliperidone palmitate), for schizophrenia (4.1% of revenues); SPRAVATO (Esketamine), a nasal spray for depression (1.8% of revenues); OPSUMIT (macitentan)/OPSYNVI (macitentan/tadalafil) for pulmonary arterial hypertension (2.5% of revenues); and UPTRAVI (selexipag) for pulmonary arterial hypertension (2.0% of revenues). The MedTech division produces products used for cardiovascular (9.5% of revenues), orthopaedics (DePuy Synthes) (9.8% of revenues), surgery (Ethicon) (10.8% of revenues), and vision treatments (Johnson & Johnson Vision) (5.8% of revenues). | 2026-05-28 15:05:01 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 367,000,000,000 | 15,000,000,000 | 4.2614 | 2,409,898,936 | 2,282,243 | 0.0948 |
| 2024 | 352,000,000,000 | -78,000,000,000 | -18.1395 | 2,407,616,693 | -1,150,535 | -0.0478 |
| 2023 | 430,000,000,000 | -42,000,000,000 | -8.8983 | 2,408,767,228 | -195,519,075 | -7.5076 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| J. Duato | CEO, Chairman | 2025 | 1,600,000 | 0 | 15,028,948 | 4,298,700 | 601,231 | 32,758,111 |
| T. Schmid | EVP | 2024 | 896,308 | 0 | 3,012,514 | 1,392,200 | 4,051,929 | 11,862,938 |
| J. Duato | CEO, Chairman | 2024 | 1,600,000 | 0 | 10,787,159 | 3,981,050 | 320,160 | 24,302,360 |
| A. Mcevoy | EVP | 2023 | 1,059,231 | 0 | 4,015,750 | 1,261,500 | 47,665 | 9,403,150 |
| J. Duato | CEO, Chairman | 2023 | 1,584,615 | 0 | 11,182,143 | 4,378,500 | 241,992 | 28,397,240 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 138,200 |
| 2024 | 138,100 |
| 2023 | 152,700 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 94,193,000,000 | 88,821,000,000 | 85,159,000,000 |
| Cost Of Revenue | 30,256,000,000 | 27,471,000,000 | 26,553,000,000 |
| Gross Profit | 63,937,000,000 | 61,350,000,000 | 58,606,000,000 |
| Research And Development Expenses | 109,000,000 | 1,841,000,000 | 483,000,000 |
| General And Administrative Expenses | 23,676,000,000 | 22,869,000,000 | 21,512,000,000 |
| Operating Expenses | 31,356,000,000 | 44,663,000,000 | 43,544,000,000 |
| Operating Income | 32,581,000,000 | 16,687,000,000 | 15,062,000,000 |
| Net Income | 26,804,000,000 | 14,066,000,000 | 35,153,000,000 |
| Earnings Per Share Basic | 11.13 | 5.84 | 13.88 |
| Earnings Per Share Diluted | 11.03 | 5.79 | 13.72 |
| Weighted Average Shares Outstanding Basic | 2,407,400,000 | 2,407,300,000 | 2,533,500,000 |
| Weighted Average Shares Outstanding Diluted | 2,429,400,000 | 2,429,400,000 | 2,560,400,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 19,709,000,000 | 24,105,000,000 | 21,859,000,000 |
| Marketable Securities Current | 393,000,000 | 417,000,000 | 1,068,000,000 |
| Accounts Receivable | 17,178,000,000 | 14,842,000,000 | 14,873,000,000 |
| Inventories | 14,191,000,000 | 12,444,000,000 | 11,181,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 4,153,000,000 | 4,085,000,000 | 4,514,000,000 |
| Total Assets Current | 55,624,000,000 | 55,893,000,000 | 53,495,000,000 |
| Marketable Securities Non Current | 665,000,000 | 451,000,000 | 4,473,000,000 |
| Property Plant And Equipment | 23,169,000,000 | 20,518,000,000 | 19,898,000,000 |
| Other Assets Non Current | 14,368,000,000 | 11,414,000,000 | 14,153,000,000 |
| Total Assets Non Current | 89,392,000,000 | 70,670,000,000 | 54,832,000,000 |
| Total Assets | 199,210,000,000 | 180,104,000,000 | 167,558,000,000 |
| Accounts Payable | 11,991,000,000 | 10,311,000,000 | 9,632,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 8,500,000,000 | 6,000,000,000 | 3,500,000,000 |
| Other Liabilities Current | 8,594,000,000 | 8,549,000,000 | 10,212,000,000 |
| Total Liabilities Current | 54,126,000,000 | 50,321,000,000 | 46,282,000,000 |
| Long Term Debt | 41,438,000,000 | 32,400,000,000 | 27,350,000,000 |
| Other Liabilities Non Current | 9,868,000,000 | 17,549,000,000 | 13,398,000,000 |
| Total Liabilities Non Current | 63,540,000,000 | 58,293,000,000 | 52,502,000,000 |
| Total Liabilities | 117,666,000,000 | 108,614,000,000 | 98,784,000,000 |
| Common Stock | 3,120,000,000 | 3,120,000,000 | 3,120,000,000 |
| Retained Earnings | 168,978,000,000 | 155,791,000,000 | 153,843,000,000 |
| Accumulated Other Comprehensive Income | -14,930,000,000 | -11,741,000,000 | -12,527,000,000 |
| Total Shareholders Equity | 81,544,000,000 | 71,490,000,000 | 68,774,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 7,503,000,000 | 7,339,000,000 | 7,486,000,000 |
| Share Based Compensation Expense | 1,354,000,000 | 1,176,000,000 | 1,162,000,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 1,781,000,000 | 406,000,000 | 624,000,000 |
| Change In Inventories | 1,450,000,000 | 1,128,000,000 | 1,323,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 6,167,000,000 | -1,717,000,000 | 3,480,000,000 |
| Change In Accounts Payable | 2,377,000,000 | 1,621,000,000 | 2,346,000,000 |
| Change In Other Liabilities | -5,697,000,000 | 33,000,000 | 5,588,000,000 |
| Cash From Operating Activities | 24,530,000,000 | 24,266,000,000 | 22,791,000,000 |
| Purchases Of Marketable Securities | 920,000,000 | 1,726,000,000 | 10,906,000,000 |
| Sales Of Marketable Securities | 1,661,000,000 | 2,462,000,000 | 19,390,000,000 |
| Acquisition Of Property Plant And Equipment | 4,832,000,000 | 4,424,000,000 | 4,543,000,000 |
| Acquisition Of Business | 17,541,000,000 | 15,146,000,000 | 0 |
| Other Investing Activities | 162,000,000 | 174,000,000 | -12,000,000 |
| Cash From Investing Activities | -23,588,000,000 | -18,599,000,000 | 878,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 12,381,000,000 | 11,823,000,000 | 11,770,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 5,953,000,000 | 2,432,000,000 | 5,054,000,000 |
| Issuance Of Long Term Debt | 9,138,000,000 | 6,660,000,000 | 0 |
| Repayment Of Long Term Debt | 1,757,000,000 | 1,453,000,000 | 1,551,000,000 |
| Other Financing Activities | -34,000,000 | -38,000,000 | -269,000,000 |
| Cash From Financing Activities | -5,539,000,000 | -3,132,000,000 | -15,825,000,000 |
| Change In Cash | -4,396,000,000 | 2,246,000,000 | 7,732,000,000 |
| Cash At End Of Period | 19,709,000,000 | 24,105,000,000 | 21,859,000,000 |
| Income Taxes Paid | 6,539,000,000 | 6,714,000,000 | 8,574,000,000 |
| Interest Paid | 1,977,000,000 | 1,990,000,000 | 1,836,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 11.13 | 5.84 | 13.88 |
| Price To Earnings Ratio | 18.6487 | 24.5445 | 11.2925 |
| Earnings Growth Rate | 90.5822 | -57.9251 | 103.2211 |
| Price Earnings To Growth Ratio | 0.2059 | -0.4237 | 0.1094 |
| Book Value Per Share | 33.8722 | 29.6972 | 27.1458 |
| Price To Book Ratio | 6.1277 | 4.8267 | 5.774 |
| Ebitda | 41,817,000,000 | 28,874,000,000 | 51,985,000,000 |
| Enterprise Value | 529,908,944,000 | 359,357,382,000 | 406,091,790,000 |
| Dividend Yield | 0.0248 | 0.0343 | 0.0296 |
| Dividend Payout Ratio | 0.4619 | 0.8405 | 0.3348 |
| Debt To Equity Ratio | 0.6124 | 0.5371 | 0.4486 |
| Capital Expenditures | 10,154,000,000 | 7,959,000,000 | 7,581,000,000 |
| Free Cash Flow | 14,376,000,000 | 16,307,000,000 | 15,210,000,000 |
| Return On Equity | 0.3287 | 0.1968 | 0.5111 |
| One Year Beta | 0.0441 | -0.047 | 0.3313 |
| Three Year Beta | 0.0922 | 0.2452 | 0.3253 |
| Five Year Beta | 0.2138 | 0.4845 | 0.5251 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| REED JOHN C | EVP, Innovative Medicine, R&D | 2026-05-01 | 25,255 | A | 35,913 |
| REED JOHN C | EVP, Innovative Medicine, R&D | 2026-05-01 | 11,002 | D | 24,911 |
| REED JOHN C | EVP, Innovative Medicine, R&D | 2026-05-01 | 25,255 | D | 0 |
| Beckerle Mary C | Director | 2026-04-23 | 975 | A | 16,797 |
| Doudna Jennifer A | Director | 2026-04-23 | 975 | A | 10,899 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| John Boozman | Senator | 2026-04-14 | Sale (Partial) | 2026-03-19 | Joint | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2024-11-15 | Sale (Full) | 2024-10-29 | Joint | $15,001 - $50,000 |
| Sheldon Whitehouse | Senator | 2024-08-21 | Sale (Full) | 2024-07-03 | Self | $15,001 - $50,000 |
| Sheldon Whitehouse | Senator | 2024-08-21 | Sale (Full) | 2024-07-03 | Spouse | $15,001 - $50,000 |
| Jerry Moran | Senator | 2024-01-17 | Sale (Full) | 2023-12-14 | Spouse | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Thomas H. Kean | 2026-04-13 | NJ07 | Sale (Partial) | 2026-03-26 | — | $1,001 - $15,000 |
| Richard Dean Dr McCormick | 2026-04-07 | GA06 | Sale (Partial) | 2026-03-19 | — | $1,001 - $15,000 |
| Richard Dean Dr McCormick | 2026-04-07 | GA06 | Sale (Partial) | 2026-03-19 | — | $1,001 - $15,000 |
| Lloyd Doggett | 2026-04-06 | TX37 | Purchase | 2026-03-10 | — | $1,001 - $15,000 |
| Thomas H. Kean | 2026-02-19 | NJ07 | Sale (Partial) | 2026-01-23 | — | $15,001 - $50,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| FLAGSHIP WEALTH ADVISORS, LLC | 2026-03-31 | 300,701 | 1,969 | 152.7176 |
| Caerus Investment Advisors, LLC | 2026-03-31 | 738,698 | 3,022 | 244.4401 |
| Integrated Investment Consultants, LLC | 2026-03-31 | 2,769,660 | 11,331 | 244.4321 |
| Concorde Asset Management, LLC | 2026-03-31 | 754,779 | 3,088 | 244.4233 |
| Foguth Wealth Management, LLC. | 2026-03-31 | 427,231 | 1,896 | 225.3328 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| World Funds Trust | 2026-04-30 | Class R Shares | KNGRX | 3,208 | 737,358.8 | 1.4682 |
| World Funds Trust | 2026-04-30 | Class Y Shares | KNGYX | 3,208 | 737,358.8 | 1.4682 |
| World Funds Trust | 2026-04-30 | Institutional Class Shares | KNGIX | 3,208 | 737,358.8 | 1.4682 |
| World Funds Trust | 2026-04-30 | Investor Class Shares | KNGLX | 3,208 | 737,358.8 | 1.4682 |
| World Funds Trust | 2026-04-30 | Class C Shares | KNGCX | 3,208 | 737,358.8 | 1.4682 |